Taking aim at 340B drug program, lawmakers target both hospitals and pharma

View Article

They don’t agree on the details, but both Republicans and Democrats in the Senate are ready to ramp up oversight of a federal drug discount program that hospitals generally support — and drug makers tend to want to rein in. On its face, the increasing congressional scrutiny seems like a win for the pharmaceutical industry, which has bucked against the status quo. But lawmakers at a Tuesday hearing on the program, known as 340B, signaled an interest in taking aim at both industries.